Jump to content

Here are the top-performing technology stocks of 2021


MongiIG

Recommended Posts

image.png

image.png

image.png

Technology stocks have been far from a sure bet since 2021 began its stretch run in mid-November. Inflationary concerns and fears of rising interest rates pushed investors out of software and internet companies, sending scores of prior outperformers into correction territory.

Despite the sell-off and the volatility across wide swaths of the tech industry, investors have made a bundle of money betting on specific companies and stories. Certain areas of the semiconductor market ballooned this year, as demand soared for processors that could speed crypto mining, aid game development and connect more devices to the internet.

 

Fintech, cloud software and cybersecurity had their share of standouts as well, even if buying baskets of those stocks and holding them for the year would not have been a particularly lucrative investment.

Here are the five biggest gainers in 2021 among U.S. tech companies valued at $5 billion or more. The list excludes companies that went public this year. Prices are as of Thursday’s close. CNBC

image.png

Link to comment
15 hours ago, Dandeli said:

How about Quest Diagnostics and Labcorp?

Hi @Dandeli

Thanks for reaching out.

image.png

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

Quest reimagines diagnostics - Interbrand

 

Here are three of the most important factors that make the stock of this medical laboratory operator a great growth pick right now.

 

Earnings Growth

Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Quest Diagnostics is 22.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 24.8% this year, crushing the industry average, which calls for EPS growth of 14.6%.

Impressive Asset Utilization Ratio

Asset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.

 

Right now, Quest Diagnostics has an S/TA ratio of 0.81, which means that the company gets $0.81 in sales for each dollar in assets. Comparing this to the industry average of 0.78, it can be said that the company is more efficient.

In addition to efficiency in generating sales, sales growth plays an important role. And Quest Diagnostics is well positioned from a sales growth perspective too. The company's sales are expected to grow 11% this year versus the industry average of 10.5%.

Promising Earnings Estimate Revisions

Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Quest Diagnostics have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.6% over the past month.

Bottom Line

Quest Diagnostics has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

For more on this article: entrepreneur.com

Link to comment
5 minutes ago, MongiIG said:

Hi @Dandeli

Thanks for reaching out.

image.png

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

Quest reimagines diagnostics - Interbrand

 

Here are three of the most important factors that make the stock of this medical laboratory operator a great growth pick right now.

 

Earnings Growth

Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Quest Diagnostics is 22.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 24.8% this year, crushing the industry average, which calls for EPS growth of 14.6%.

Impressive Asset Utilization Ratio

Asset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.

 

Right now, Quest Diagnostics has an S/TA ratio of 0.81, which means that the company gets $0.81 in sales for each dollar in assets. Comparing this to the industry average of 0.78, it can be said that the company is more efficient.

In addition to efficiency in generating sales, sales growth plays an important role. And Quest Diagnostics is well positioned from a sales growth perspective too. The company's sales are expected to grow 11% this year versus the industry average of 10.5%.

Promising Earnings Estimate Revisions

Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Quest Diagnostics have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.6% over the past month.

Bottom Line

Quest Diagnostics has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

For more on this article: entrepreneur.com

image.png

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Quest Diagnostics (DGX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

More on this article: nasdaq.com

Brand New: New Logo and Identity for Quest Diagnostics by InterbrandHealth

Link to comment
15 hours ago, Dandeli said:

How about Quest Diagnostics and Labcorp?

Hi @Dandeli

Thanks for reaching out.

image.png

Labcorp Jobs and Company Culture

Global life sciences company Laboratory Corporation of America Holdings (NYSE: LH), popularly known as Labcorp, entered into a definitive agreement to acquire cancer genomics solutions provider, Personal Genome Diagnostics Inc. for $575 million. The deal is likely to close in the first half of 2022.

Following the news, shares of the company declined marginally to close at $301.91 during yesterday’s extended trading session.

Terms of the Deal

Under the terms of the deal, Labcorp will initially pay $450 million in cash and an additional $125 million, subject to the achievement of certain milestones.

Strategic Impact

With this acquisition, Labcorp will gain access to Personal Genome’s advanced cancer genomics technology and subsequently gain a strong foothold in the space. Along with its existing liquid biopsy capabilities, Labcorp’s oncology portfolio will also receive a boost resulting in enhanced offerings for its patients.

Financial Implications of the Deal

Personal Genome is expected to register revenues of about $22 million in 2021 and about $40 million in 2022. Taking this into account, Labcorp expects the acquisition to be slightly dilutive to Labcorp’s adjusted earnings per share over the next couple of years. However, the acquisition will provide returns in excess of its cost of capital by year five.

Management Commentary

CEO of Labcorp, Adam Schechter, said "PGDx’s comprehensive portfolio of next-generation sequencing products will meaningfully add to our breadth of capabilities, in line with our strategic priority to lead in oncology. PGDx’s technology is well positioned in an important segment with strong growth prospects.”

Analyst Ratings

Recently, Mizuho Securities analyst Ann Hynes reiterated a Buy rating on the stock. The analyst, however, raised the price target from $332 to $354, which implies upside potential of 17.3% from current levels.

Wall Street Analysts Ratings is a Strong Buy based on 7 Buys and 1 Hold. The average Labcorp stock price prediction price target of $353.13 implies upside potential of 16.97% from current levels. Shares have gained 48.1% over the past year.

LH-1024x346.jpg

nasdaq.com

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
      22,973
    • Total Posts
      95,277
    • Total Members
      43,582
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    1962Dave
    Joined 21/09/23 12:42
  • Posts

    • Dow, Nasdaq 100 and Nikkei 225 all fall back after hawkish Fed decision The Fed’s ‘hawkish pause’ has sent markets into a tailspin, with stocks falling as investors contemplate the prospect of a much longer period of higher interest rates in the US. Source: Bloomberg  Chris Beauchamp | Chief Market Analyst, London | Publication date: Thursday 21 September 2023 11:43 Dow slumps following Fed decision The index saw a substantial reversal yesterday, and has moved back towards the lows of last week. The 100-day SMA could now provide some support, but below this the 34,000 level and the 200-day SMA could also see some buying emerge. A revival above 35,000 would be needed to secure a more bullish short-term view. Source:ProRealTime Nasdaq 100 gives back more gains Losses continue here, with yesterday’s drop further eating into the gains made from the August lows. The price is currently sitting on the 100-day SMA, and a close below this opens the way in short order to 14,690. Below this the August low at 14,500 comes into view. From here, the next major level to watch would be the August 2022 high at 13,722. A rally above 15,300 would be needed to suggest that the buyers have succeeded in reasserting control. Source:ProRealTime Nikkei 225 sees further losses The drift lower of earlier in the week has turned into a more dramatic move lower. This has put the sellers back in control. Below the 50- and 100-day SMAs, the price then moves on to target 32,076, and then to the August low at 31,295. Buyers will want to see a move back above 33,000 to suggest that the selling has been halted for the time being. Source:ProRealTime
    • Brent crude oil, gold and natural gas prices drop post hawkish Fed pause Outlook on Brent crude oil, gold and natural following Fed’s hawkish pause. Source: Bloomberg  Axel Rudolph FSTA | Senior Financial Analyst, London | Publication date: Thursday 21 September 2023 11:27 Brent crude oil comes off its ten-month high The price of Brent crude oil continues to come off Tuesday’s ten-month high at $94.97 while the US dollar once more appreciates, exerting a slight downward pressure on the oil price, and as the Fed delivered a hawkish pause. Support can be spotted around the $90.97 early September high ahead of the psychological $90.00 mark. Resistance lurks around Tuesday’s $93.32 low. Further up lies this week’s ten-month high at $94.97 and the mid-September 2022 high at $95.19. Source: ProRealTime Gold comes off yesterday’s $1,947 high Gold rallied back towards its $1,953 per troy ounce early September high but only managed to reach $1,947 before it came off again as the greenback continued to appreciate following hawkish comments at the Federal Open Market Committee (FOMC). The 200-day simple moving average (SMA) at $1,925 is currently being probed as support, below which the 6 September low at $1,915 may also act as minor support. Minor resistance above the 55-day simple moving average (SMA) at $1,932 sits at Tuesday’s $1,937 high. Source: ProRealTime Natural gas comes off this week’s six-week high Natural gas prices recently shot back up to the $3.000 mark on weather and production concerns but are currently slipping back from this week’s high at $3.021. A slip through Wednesday’s $2.857 low would put Monday’s low and the 200-day simple moving average (SMA) at $2.800 to $2.791 on the map. Immediate resistance is seen at the early September high at $2.904 ahead of last and this week’s highs at $2.973 to $3.021. Slightly further up sits the August peak at $3.050. Source: ProRealTime
    • I think it comes down to marketing, community managedment, and events + ofcourse a neat interface with awesome features
×
×
  • Create New...
us